Advertisement Pharmaceutical Business review - Page 225 of 5295 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 21, 2026

Sanofi and ScionxBio partner on mRNA therapies

Sanofi has signed a global licensing and strategic collaboration agreement with UK-based biotechnology company ScionxBio to develop long-acting messenger ribonucleic acid (mRNA) therapies using the TERA platform.

The agreement combines the work of Sanofi’s mRNA Center of Excellence with ScionxBio’s computational platform. Credit: Formatoriginal / Shutterstock.com.